Visual Field Severity Indices Demonstrate Dose‐Dependent Visual Loss from Vigabatrin Therapy

Abstract

Maximum daily dose was the single most reliable indicator of those patients likely to exhibit visual field defects due to VGB. These findings suggest that high maximum dose is more likely to result in visual field defects than high cumulative doses or those of long duration.